Search research articles
Contact Us
Filters
Showing results (41-50 of 67) with videos related to
Page
of 7
Sort By:
International Journal of Hematology
|
November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Max J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Cancer Cell
|
February 5, 2010
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress
Hyun-Seok Kim, Krish Patel, Kristi Muldoon-Jacobs, et al.
BMC Cardiovascular Disorders
|
January 22, 2026
Trends and disparities in aortic dissection mortality in the united states: a retrospective analysis
Mohamed Fawzi Hemida, Alyaa Ahmed Ibrahim, Nafila Zeeshan, et al.
Blood Advances
|
March 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia
Richard R Furman, William G Wierda, Piers Em Patten, et al.
American Journal of Hematology
|
December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Blood
|
June 20, 2020
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Livia Hegerova, Ted A Gooley, Kelly A Sweerus, et al.
Haematologica
|
December 23, 2021
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, et al.
Acta Haematologica
|
June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies
Lindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Blood Advances
|
February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
Geoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 67) with videos related to
Sort By:
Page
of 7
International Journal of Hematology
|
November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model
Max J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Cancer Cell
|
February 5, 2010
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress
Hyun-Seok Kim, Krish Patel, Kristi Muldoon-Jacobs, et al.
BMC Cardiovascular Disorders
|
January 22, 2026
Trends and disparities in aortic dissection mortality in the united states: a retrospective analysis
Mohamed Fawzi Hemida, Alyaa Ahmed Ibrahim, Nafila Zeeshan, et al.
Blood Advances
|
March 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia
Richard R Furman, William G Wierda, Piers Em Patten, et al.
American Journal of Hematology
|
December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Blood
|
June 20, 2020
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Livia Hegerova, Ted A Gooley, Kelly A Sweerus, et al.
Haematologica
|
December 23, 2021
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, et al.
Acta Haematologica
|
June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies
Lindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Blood Advances
|
February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
Geoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Page
of 7